NMDA receptors and schizophrenia

Curr Opin Pharmacol. 2007 Feb;7(1):48-55. doi: 10.1016/j.coph.2006.08.013. Epub 2006 Nov 9.


The pathophysiology of schizophrenia is poorly understood but is likely to involve alterations in excitatory glutamatergic signaling molecules in several areas of the brain. Clinical and experimental evidence has shown that expression of the N-methyl-D-aspartate (NMDA) receptor and intracellular NMDA receptor-interacting proteins of the glutaminergic synapse appear to be dysregulated in schizophrenia. It has been suggested that schizophrenia involves molecular changes in the glutamatergic pathways that mediate excitatory communication between multiple brain regions. Recent data also implicate abnormalities in cellular functions such as receptor trafficking and synaptic targeting.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antipsychotic Agents / therapeutic use
  • Humans
  • Receptors, N-Methyl-D-Aspartate / metabolism*
  • Schizophrenia / drug therapy
  • Schizophrenia / metabolism*


  • Antipsychotic Agents
  • Receptors, N-Methyl-D-Aspartate